LEPR (Leptin receptor) variants and mutations
LEPR (also known as Leptin receptor) is a human protein-coding gene encoding a leptin receptor protein. It transmits leptin signals to hypothalamic circuits that regulate appetite, body weight, endocrine axes, and energy expenditure. Biallelic loss-of-function variants cause severe early-onset obesity with intense hyperphagia and frequently hypogonadotropic hypogonadism. This analysis covers 1,511 LEPR variants and mutations. Of these, 69% have computational variant effect predictions. Disease context includes obesity due to leptin receptor gene deficiency, lipodystrophy, and type 2 diabetes mellitus. Example LEPR variants include M1?, I2T, and I2V.
Variant analysis overview
- Gene: LEPR
- Protein: Leptin receptor
- UniProt accession: P48357
- Organism: Homo sapiens
- Variants analyzed: 1511
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,317 unspecified-consequence records; 63 synonymous variants; 103 missense variants; 13 frameshift variants; 11 stop-gained variants; 2 in-frame deletions; 2 splice-region variants
- Prediction scores: 1,039 variants have prediction scores (69% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: obesity due to leptin receptor gene deficiency, lipodystrophy, type 2 diabetes mellitus, obesity disorder, diabetes mellitus, Abnormality of the skeletal system, familial partial lipodystrophy, liver disorder, Obesity, generalized lipodystrophy, metabolic dysfunction-associated steatohepatitis, morbid obesity.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 5 domains; 22 post-translational modification sites.
- Structural context: 549 variants have structural context.
- PTM context: 27 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable LEPR variants
Examples include M1?, I2T, I2V, C3S, C3C, Q4H, Q4Q, K5N. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV6074, NCI-TCGA Cosmic COSV6076, cosmic curated COSV60764, Variant assessed as somatic; high impact.
- I2T (p.Ile2Thr), TOPMed rs755942457, gnomAD rs755942457
- I2V (p.Ile2Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C3S (p.Cys3Ser), Ensembl rs941469900
- C3C (p.Cys3Cys), gnomAD 1-65565574-T-C, CADD 13.10
- Q4H (p.Gln4His), gnomAD 1-65565577-A-C, REVEL 0.03, CADD 15.40
- Q4Q (p.Gln4Gln), rs1172543119, gnomAD 1-65565577-A-G, CADD 8.88
- K5N (p.Lys5Asn), ExAC rs780405424, TOPMed rs780405424, gnomAD rs780405424, REVEL 0.09, CADD 19.30
- K5T (p.Lys5Thr), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10075, REVEL 0.05, CADD 20.90, Variant assessed as somatic; moderate impact.
- K5K (p.Lys5Lys), rs780405424, gnomAD 1-65565580-A-G, CADD 7.82
- F6L (p.Phe6Leu), cosmic curated COSV60751, TOPMed rs1465011978, gnomAD rs1465011978, REVEL 0.02, CADD 20.20
- F6F (p.Phe6Phe), rs1465011978, gnomAD 1-65565583-C-T, CADD 14.60
- C7Y (p.Cys7Tyr), ExAC rs754290111, TOPMed rs754290111, gnomAD rs754290111, REVEL 0.05, CADD 0.03
- C7F (p.Cys7Phe), gnomAD 1-65565585-G-T, REVEL 0.06, CADD 0.27
- V8L (p.Val8Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V8M (p.Val8Met), gnomAD 1-65565587-G-A, REVEL 0.04, CADD 19.80
- V8V (p.Val8Val), gnomAD 1-65565589-G-A, CADD 15.80
- V9A (p.Val9Ala), ExAC rs755465413, TOPMed rs755465413, gnomAD rs755465413, REVEL 0.03, CADD 13.80, Uncertain significance, LEPR-related disorder
- V9I (p.Val9Ile), gnomAD 1-65565590-G-A, REVEL 0.03, CADD 16.00
- L10F (p.Leu10Phe), TOPMed rs1390307326, REVEL 0.04, CADD 13.80
- L10L (p.Leu10Leu), gnomAD 1-65565593-T-C, CADD 9.97
- L11F (p.Leu11Phe), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10075, Variant assessed as somatic; moderate impact.
- H12R (p.His12Arg), TOPMed rs1465098791, gnomAD rs1465098791, REVEL 0.01, CADD 8.18
- H12H (p.His12His), rs147768538, gnomAD 1-65565601-T-C, CADD 0.28
- W13* (p.Trp13Ter), Ensembl rs2100783495
- W13C (p.Trp13Cys), cosmic curated COSV10075, 1000Genomes rs142395970, ESP rs142395970, ExAC rs142395970, REVEL 0.16, CADD 18.40
- E14G (p.Glu14Gly), gnomAD rs1396906830, REVEL 0.18, CADD 22.50
- E14K (p.Glu14Lys), gnomAD rs1653678733, REVEL 0.12, CADD 29.50
- I16T (p.Ile16Thr), ExAC rs766684961, TOPMed rs766684961, gnomAD rs766684961, REVEL 0.23, CADD 22.90
- I16M (p.Ile16Met), gnomAD 1-65570473-AATTT-, CADD 25.50
- I16F (p.Ile16Phe), gnomAD 1-65570477-TA-T, CADD 22.90
- Y17* (p.Tyr17Ter), gnomAD rs1315355752, CADD 24.90
- Y17F (p.Tyr17Phe), Ensembl rs1570719356
- Y17C (p.Tyr17Cys), gnomAD 1-65570482-A-G, REVEL 0.13, CADD 10.40
- Y17Y (p.Tyr17Tyr), gnomAD 1-65570483-T-C, CADD 2.27
- V18L (p.Val18Leu), 1000Genomes rs754188832, ExAC rs754188832, TOPMed rs754188832, gnomAD rs754188832, REVEL 0.04, CADD 11.20
- V18M (p.Val18Met), 1000Genomes rs754188832, ExAC rs754188832, TOPMed rs754188832, gnomAD rs754188832, REVEL 0.03, CADD 9.72
- V18V (p.Val18Val), rs755482802, gnomAD 1-65570486-G-T, CADD 4.67
- I19K (p.Ile19Lys), gnomAD 1-65570487-AT-A, CADD 22.70
- I19T (p.Ile19Thr), gnomAD 1-65570488-T-C, REVEL 0.05, CADD 11.70
- T20N (p.Thr20Asn), Ensembl rs932745822, REVEL 0.14, CADD 22.70
- A21S (p.Ala21Ser), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10075, Variant assessed as somatic; moderate impact.
- A21T (p.Ala21Thr), TOPMed rs1654078580
- A21V (p.Ala21Val), rs779334350, NCI-TCGA Cosmic COSV6075, cosmic curated COSV60754, ExAC rs779334350, REVEL 0.35, CADD 22.80, Uncertain significance, Inborn genetic diseases
- A21A (p.Ala21Ala), rs148155161, gnomAD 1-65570495-G-A, CADD 2.90
- F22L (p.Phe22Leu), cosmic curated COSV60755, gnomAD rs1283354030, REVEL 0.03, CADD 5.67
- F22F (p.Phe22Phe), rs926586992, gnomAD 1-65570498-T-C, CADD 6.18
- N23K (p.Asn23Lys), ExAC rs758614103, TOPMed rs758614103, gnomAD rs758614103, REVEL 0.04, CADD 3.62
- N23S (p.Asn23Ser), gnomAD rs1487793938, REVEL 0.09, CADD 12.30
- L24* (p.Leu24Ter), gnomAD rs1654079716
- L24F (p.Leu24Phe), NCI-TCGA Cosmic COSV6076, cosmic curated COSV60760, Variant assessed as somatic; moderate impact.
- L24L (p.Leu24Leu), gnomAD 1-65570504-G-A, CADD 5.91
- S25A (p.Ser25Ala), gnomAD 1-65570505-T-G, REVEL 0.09, CADD 6.41
- S25* (p.Ser25Ter), gnomAD 1-65570506-C-A, CADD 34.00
- S25S (p.Ser25Ser), rs1258067883, gnomAD 1-65570507-A-T, CADD 7.17
- Y26H (p.Tyr26His), rs778003419, ClinGen CA894460, ClinVar RCV004528741, ExAC rs778003419, REVEL 0.18, CADD 16.60, Uncertain significance, LEPR-related disorder
- Y26Y (p.Tyr26Tyr), rs747170074, gnomAD 1-65570510-T-C, CADD 2.26
- P27A (p.Pro27Ala), ExAC rs757574299, TOPMed rs757574299, gnomAD rs757574299, REVEL 0.13, CADD 19.30
- P27L (p.Pro27Leu), gnomAD 1-65570512-C-T, REVEL 0.29, CADD 23.90
- I28V (p.Ile28Val), rs369475236, ClinGen CA894463, ClinVar RCV003152086, ClinVar RCV005927104, REVEL 0.03, CADD 7.18, Uncertain significance, not provided
- I28T (p.Ile28Thr), gnomAD 1-65570515-T-C, REVEL 0.02, CADD 8.81
- T29A (p.Thr29Ala), ExAC rs749087675, gnomAD rs749087675, REVEL 0.02, CADD 7.19
- T29P (p.Thr29Pro), ExAC rs749087675, gnomAD rs749087675, REVEL 0.04, CADD 3.08
- T29S (p.Thr29Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T29N (p.Thr29Asn), gnomAD 1-65570518-C-A, REVEL 0.08, CADD 11.20
- P30A (p.Pro30Ala), Ensembl rs890963440
- P30L (p.Pro30Leu), cosmic curated COSV10465, Ensembl rs1654081187
- P30S (p.Pro30Ser), NCI-TCGA Cosmic COSV1007, Variant assessed as somatic; moderate impact.
- P30H (p.Pro30His), gnomAD 1-65570521-C-A, REVEL 0.59, CADD 23.00
- P30P (p.Pro30Pro), rs560511914, gnomAD 1-65570522-T-G, CADD 6.66
- W31* (p.Trp31Ter), rs945135468, ClinGen CA16617181, ClinVar RCV000479260, ClinVar RCV004735562, CADD 36.00, Pathogenic
- W31C (p.Trp31Cys), TOPMed rs945135468, gnomAD rs945135468, Pathogenic
- W31G (p.Trp31Gly), gnomAD 1-65570523-T-G, REVEL 0.35, CADD 23.00
- R32I (p.Arg32Ile), rs1360127522, NCI-TCGA Cosmic COSV6074, cosmic curated COSV60746, gnomAD rs1360127522, REVEL 0.11, CADD 21.50, Variant assessed as somatic; moderate impact.
- R32S (p.Arg32Ser), ESP rs373650495, ExAC rs373650495, TOPMed rs373650495, gnomAD rs373650495, REVEL 0.08, CADD 21.00
- R32G (p.Arg32Gly), gnomAD 1-65570526-A-G, REVEL 0.10, CADD 22.10
- R32R (p.Arg32Arg), rs373650495, gnomAD 1-65570528-A-G, CADD 13.20
- F33L (p.Phe33Leu), ExAC rs771516633, TOPMed rs771516633, gnomAD rs771516633, NCI-TCGA TCGA novel, REVEL 0.47, CADD 25.50, Variant assessed as somatic; high impact.
- K34Q (p.Lys34Gln), TOPMed rs1654082320, gnomAD rs1654082320, REVEL 0.06, CADD 21.20
- K34M (p.Lys34Met), gnomAD 1-65570533-A-T, REVEL 0.13, CADD 22.30
- S36Y (p.Ser36Tyr), ExAC rs772735713, gnomAD rs772735713, REVEL 0.07, CADD 21.60
- C37S (p.Cys37Ser), gnomAD 1-65570542-G-C, REVEL 0.73, CADD 25.30
- C37W (p.Cys37Trp), gnomAD 1-65570543-C-G, REVEL 0.70, CADD 23.40
- M38L (p.Met38Leu), Ensembl rs574850620, REVEL 0.10, CADD 13.20
- M38T (p.Met38Thr), Ensembl rs1654082929
- M38V (p.Met38Val), gnomAD 1-65570544-A-G, REVEL 0.07, CADD 10.90
- M38I (p.Met38Ile), gnomAD 1-65570546-G-A, REVEL 0.09, CADD 15.50
- P39A (p.Pro39Ala), gnomAD rs1557669207, REVEL 0.07, CADD 16.80
- P39L (p.Pro39Leu), Ensembl rs1654083227, REVEL 0.12, CADD 16.80
- P40L (p.Pro40Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P40Q (p.Pro40Gln), Ensembl rs1570719579
- P40P (p.Pro40Pro), gnomAD 1-65570552-A-C, CADD 8.06
- N41D (p.Asn41Asp), gnomAD rs1310556138, REVEL 0.06, CADD 22.80
- S42S (p.Ser42Ser), rs1557669234, gnomAD 1-65570558-A-G, CADD 2.14
- T43A (p.Thr43Ala), ExAC rs766062837, TOPMed rs766062837, gnomAD rs766062837, REVEL 0.23, CADD 22.80, Uncertain significance, LEPR-related disorder
- T43I (p.Thr43Ile), gnomAD rs1241672391, REVEL 0.17, CADD 20.60, Uncertain significance
- T43S (p.Thr43Ser), rs1241672391, ClinGen CA340672095, ClinVar RCV003262555, gnomAD rs1241672391, REVEL 0.23, CADD 19.20, Uncertain significance, Inborn genetic diseases
- T43T (p.Thr43Thr), rs943843563, gnomAD 1-65570561-C-T, CADD 0.21
- Y44N (p.Tyr44Asn), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10075, Variant assessed as somatic; moderate impact.
- Y44S (p.Tyr44Ser), gnomAD 1-65570563-A-C, REVEL 0.04, CADD 7.10
- D45G (p.Asp45Gly), NCI-TCGA Cosmic COSV6076, cosmic curated COSV60765, Uncertain significance, Inborn genetic diseases
- D45V (p.Asp45Val), ExAC rs777028748, gnomAD rs777028748, REVEL 0.23, CADD 12.40
- Y46* (p.Tyr46Ter), rs757358893, ClinGen CA894473, ClinVar RCV002226617, ClinVar RCV003708622, CADD 17.10, Pathogenic
- Y46C (p.Tyr46Cys), TOPMed rs1482124619, gnomAD rs1482124619, REVEL 0.06, CADD 10.40
- Y46H (p.Tyr46His), cosmic curated COSV60752, ExAC rs759874242, TOPMed rs759874242, gnomAD rs759874242, REVEL 0.11, CADD 1.00
- Y46F (p.Tyr46Phe), gnomAD 1-65570569-A-T, REVEL 0.05, CADD 0.30
- F47L (p.Phe47Leu), ExAC rs765766605, gnomAD rs765766605, REVEL 0.10, CADD 8.52
- F47F (p.Phe47Phe), gnomAD 1-65570573-C-T, CADD 1.45
- L48F (p.Leu48Phe), ExAC rs753075938, TOPMed rs753075938, gnomAD rs753075938, REVEL 0.11, CADD 8.02
- L49* (p.Leu49Ter), TOPMed rs1654085778
- L49S (p.Leu49Ser), TOPMed rs1654085778
- P50H (p.Pro50His), gnomAD 1-65570581-C-A, REVEL 0.21, CADD 19.50
- P50L (p.Pro50Leu), gnomAD 1-65570581-C-T, REVEL 0.12, CADD 15.40
- A51D (p.Ala51Asp), NCI-TCGA Cosmic COSV6075, cosmic curated COSV60750, Variant assessed as somatic; moderate impact.
- A51P (p.Ala51Pro), 1000Genomes rs201975519, ExAC rs201975519, gnomAD rs201975519, REVEL 0.04, CADD 1.88
- G52A (p.Gly52Ala), ExAC rs764219691, TOPMed rs764219691, gnomAD rs764219691, REVEL 0.25, CADD 23.60
- G52E (p.Gly52Glu), ExAC rs764219691, TOPMed rs764219691, gnomAD rs764219691, REVEL 0.21, CADD 24.00
- G52V (p.Gly52Val), ExAC rs764219691, TOPMed rs764219691, gnomAD rs764219691, REVEL 0.31, CADD 24.00, Uncertain significance, Inborn genetic diseases
- G52G (p.Gly52Gly), gnomAD 1-65570588-A-G, CADD 8.22
- K55N (p.Lys55Asn), rs2100804678, ClinGen CA340672212, NCI-TCGA Cosmic COSV6075, cosmic curated COSV60754, REVEL 0.03, CADD 8.19, Uncertain significance, not specified
- K55Q (p.Lys55Gln), gnomAD 1-65570588-A-ACT, CADD 23.40
- K55E (p.Lys55Glu), gnomAD 1-65570595-A-G, REVEL 0.04, CADD 5.96
- K55T (p.Lys55Thr), gnomAD 1-65570596-A-C, REVEL 0.04, CADD 6.66
- K55R (p.Lys55Arg), gnomAD 1-65570596-A-G, REVEL 0.04, CADD 5.50
- N56H (p.Asn56His), gnomAD 1-65570598-A-C, REVEL 0.11, CADD 18.30
- N56T (p.Asn56Thr), gnomAD 1-65570599-A-C, REVEL 0.05, CADD 12.40
- T57I (p.Thr57Ile), gnomAD 1-65570602-C-T, REVEL 0.09, CADD 3.27
- T57T (p.Thr57Thr), rs1654086589, gnomAD 1-65570603-T-G, CADD 4.98
- S58* (p.Ser58Ter), TOPMed rs1379819290, gnomAD rs1379819290
- S58L (p.Ser58Leu), TOPMed rs1379819290, gnomAD rs1379819290, REVEL 0.23, CADD 23.40
- S58P (p.Ser58Pro), ESP rs150657671, TOPMed rs150657671, gnomAD rs150657671, REVEL 0.22, CADD 22.50
- S58T (p.Ser58Thr), ESP rs150657671, TOPMed rs150657671, gnomAD rs150657671, REVEL 0.13, CADD 22.80
- S58S (p.Ser58Ser), rs1654087106, gnomAD 1-65570606-A-G, CADD 0.66
- S60A (p.Ser60Ala), TOPMed rs1429181930
- S60L (p.Ser60Leu), rs1433955773, NCI-TCGA Cosmic COSV6075, cosmic curated COSV60758, NCI-TCGA Cosmic COSV6076, REVEL 0.04, CADD 0.01, Uncertain significance, LEPR-related disorder
- S60W (p.Ser60Trp), NCI-TCGA Cosmic COSV6075, NCI-TCGA Cosmic COSV6076, cosmic curated COSV60762, Variant assessed as somatic; moderate impact.
- S60S (p.Ser60Ser), rs376850470, gnomAD 1-65570612-G-A, CADD 2.15
- N61S (p.Asn61Ser), ESP rs370723424, ExAC rs370723424, TOPMed rs370723424, gnomAD rs370723424, REVEL 0.04, CADD 0.43
- N61N (p.Asn61Asn), rs897058665, gnomAD 1-65570615-T-C, CADD 3.44
- G62E (p.Gly62Glu), gnomAD rs1332537723, REVEL 0.09, CADD 14.00
- G62R (p.Gly62Arg), gnomAD 1-65570616-G-A, REVEL 0.10, CADD 19.00
- G62G (p.Gly62Gly), gnomAD 1-65570618-A-T, CADD 4.75
- H63R (p.His63Arg), ExAC rs781329053, gnomAD rs781329053, REVEL 0.04, CADD 0.07
- Y64C (p.Tyr64Cys), gnomAD rs1445275733, REVEL 0.16, CADD 17.40
- Y64F (p.Tyr64Phe), NCI-TCGA Cosmic COSV6075, cosmic curated COSV60759, REVEL 0.09, CADD 6.98, Variant assessed as somatic; moderate impact.
- Y64H (p.Tyr64His), TOPMed rs1484674491, gnomAD rs1484674491, REVEL 0.05, CADD 4.24
- Y64S (p.Tyr64Ser), gnomAD rs1445275733
- E65D (p.Glu65Asp), NCI-TCGA Cosmic COSV6074, cosmic curated COSV60748, Variant assessed as somatic; moderate impact.
- E65K (p.Glu65Lys), Ensembl rs868646648
- T66I (p.Thr66Ile), TOPMed rs997252375, Uncertain significance
- T66K (p.Thr66Lys), rs997252375, ClinGen CA340672333, ClinVar RCV003309966, TOPMed rs997252375, AlphaMissense 0.11, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- T66P (p.Thr66Pro), 1000Genomes rs561158528, ExAC rs561158528, gnomAD rs561158528, REVEL 0.07, CADD 7.56
- T66A (p.Thr66Ala), gnomAD 1-65570628-A-G, REVEL 0.08, CADD 1.45
- T66T (p.Thr66Thr), gnomAD 1-65570630-A-T, CADD 4.04
- A67D (p.Ala67Asp), ExAC rs573025358, TOPMed rs573025358, gnomAD rs573025358, REVEL 0.07, CADD 4.24
- A67S (p.Ala67Ser), gnomAD 1-65570631-G-T, REVEL 0.03, CADD 0.09
- V68* (p.Val68Ter), gnomAD 1-65570631-GCTGTT, CADD 24.60
- V68I (p.Val68Ile), gnomAD 1-65570634-G-A, REVEL 0.05, CADD 3.79
- E69Q (p.Glu69Gln), gnomAD 1-65570637-G-C, REVEL 0.12, CADD 22.60
- P70R (p.Pro70Arg), NCI-TCGA Cosmic COSV6076, cosmic curated COSV60765, TOPMed rs1654089593, REVEL 0.07, CADD 9.82, Variant assessed as somatic; moderate impact.
- P70S (p.Pro70Ser), 1000Genomes rs531684351, ExAC rs531684351, gnomAD rs531684351, REVEL 0.04, CADD 8.09, Uncertain significance, LEPR-related disorder
- P70T (p.Pro70Thr), 1000Genomes rs531684351, ExAC rs531684351, gnomAD rs531684351, REVEL 0.12, CADD 6.90, Uncertain significance
- P70L (p.Pro70Leu), gnomAD 1-65570641-C-T, REVEL 0.08, CADD 7.65
- K71T (p.Lys71Thr), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10075, REVEL 0.06, CADD 9.40, Variant assessed as somatic; moderate impact.
- S74* (p.Ser74Ter), NCI-TCGA Cosmic COSV6075, cosmic curated COSV60752, Variant assessed as somatic; high impact.
- S74L (p.Ser74Leu), gnomAD 1-65570653-C-T, REVEL 0.03, CADD 15.20
- S75R (p.Ser75Arg), TOPMed rs1654089862, gnomAD rs1654089862, REVEL 0.09, CADD 18.00
- S75S (p.Ser75Ser), rs1654090017, gnomAD 1-65570657-T-C, CADD 5.02
- G76D (p.Gly76Asp), rs748033432, NCI-TCGA Cosmic COSV6074, cosmic curated COSV60747, NCI-TCGA Cosmic COSV9905, REVEL 0.04, CADD 0.81, Variant assessed as somatic; moderate impact.
- G76S (p.Gly76Ser), gnomAD 1-65570658-G-A, REVEL 0.04, CADD 8.20
- T77A (p.Thr77Ala), Ensembl rs766147770, REVEL 0.05, CADD 0.47
- H78L (p.His78Leu), gnomAD rs1310080000
- H78P (p.His78Pro), gnomAD rs1310080000, REVEL 0.21, CADD 11.80
- H78Y (p.His78Tyr), NCI-TCGA Cosmic COSV6075, cosmic curated COSV60759, NCI-TCGA Cosmic COSV6076, Ensembl rs2100804914, Variant assessed as somatic; moderate impact.
- H78H (p.His78His), gnomAD 1-65570666-C-T, CADD 3.54
- F79S (p.Phe79Ser), ESP rs144695935, ExAC rs144695935
- F79Y (p.Phe79Tyr), gnomAD 1-65570668-T-A, REVEL 0.06, CADD 8.55
- S80S (p.Ser80Ser), rs1222670770, gnomAD 1-65570672-T-C, CADD 2.37
- N81D (p.Asn81Asp), ExAC rs772680635, TOPMed rs772680635, gnomAD rs772680635, REVEL 0.08, CADD 4.89
- N81S (p.Asn81Ser), cosmic curated COSV60762, TOPMed rs1654091044, REVEL 0.12, CADD 6.94
Public LEPR analysis runs
- LEPR analysis run — LEPR (1,511 variants) — completed 2026-08-19